{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:48Z","timestamp":1790983128313,"version":"4.1.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP26fk0310529, JP26fk0210174"],"award-info":[{"award-number":["JP26fk0310529, JP26fk0210174"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K11170"],"award-info":[{"award-number":["JP25K11170"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced hepatocellular carcinoma (HCC), but severe multisystem immune-related adverse events (irAEs) remain a major clinical challenge. We report an autopsy-confirmed case of advanced HCC treated with tremelimumab plus durvalumab that developed severe metachronous multisystem irAEs characterized by sequential pancreatitis, laryngeal edema with sialadenitis, and myocarditis. Twelve days after treatment initiation, the patient presented with fever and abdominal distension, and computed tomography showed CTCAE grade 3 pancreatitis. On hospital day 6, he developed life-threatening laryngeal edema requiring intubation and steroid pulse therapy. Although the airway edema improved, complete atrioventricular block developed on day 23. Cardiac troponin I increased to 42,006 pg\/mL, and endomyocardial biopsy demonstrated CD8-predominant myocarditis consistent with CTCAE grade 4 irAE. Cardiac conduction recovered after additional corticosteroid therapy, but the patient subsequently died of septic shock. Autopsy revealed CD8-positive lymphocytic infiltration not only in clinically recognized irAE-affected organs, including the pancreas, salivary glands, pharynx\/larynx, and heart, but also in clinically silent organs, including the kidneys and intestine, indicating widespread subclinical immune-mediated injury. Multiplex immunofluorescence analysis demonstrated CD3-positive T-cell infiltration enriched for CD8-positive T cells, with variable or focal Granzyme B expression across affected tissues. In contrast, CD68-positive macrophages and CD66b-positive neutrophils were not the dominant inflammatory populations. This clinicopathological autopsy case supports the concept that clinically apparent irAEs may represent only the visible portion of systemic CD8-positive T-cell\u2013dominant immune-mediated injury. Severe irAEs after tremelimumab plus durvalumab therapy may progress metachronously and involve clinically silent organs beyond those recognized during life, highlighting the need for continued multisystem monitoring after the onset of severe irAEs.<\/jats:p>","DOI":"10.3389\/fonc.2026.1830325","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:51:12Z","timestamp":1785905472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Takuto","family":"Nosaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Imamura","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology\/Surgical Pathology, University of Fukui Hospital","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: Emerging challenges in clinical practice","volume":"8","author":"Pinter","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100683","article-title":"Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: An autopsy study over 13 -years","volume":"38","author":"Maccio","year":"2025","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001385","article-title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hcc: Himalaya phase iii randomized clinical trial","volume":"83","author":"Lau","year":"2026","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (Sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40959-025-00404-8","article-title":"How should immune checkpoint inhibitor myocarditis be treated","volume":"11","author":"Badaan","year":"2025","journal-title":"Cardiooncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13346","article-title":"Immune checkpoint inhibitors and infection: What is the interplay","volume":"37","author":"Papadakis","year":"2023","journal-title":"In Vivo"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4393","article-title":"Infectious complications of immune checkpoint inhibitors in solid organ Malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:51:27Z","timestamp":1785905487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1830325"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1830325","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1830325"}}